evidence: In patients with a high disease activity at baseline, the clinical efficacy of abatacept was similar to adalimumab and tocilizumab.
intervention: abatacept
comparator: TNF-alpha treatment
outcome: Juvenile Idiopathic Arthritis (JIA) - proportion of patients relapsed after stopping the treatment